Literature DB >> 14743400

Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells.

Kenneth M Sterling1, Kenneth R Cutroneo.   

Abstract

Constitutive and benzo[a]pyrene (B[a]P) inducible expression of CYP1A1 and CYP1A2 in prostate cancer and normal prostate epithelial cells were examined by immunoblotting. Androgen independent prostate cancer cell lines DU145 and PC3 have constitutive expression of CYP1A and CYP1A1 and CYP1A2, respectively. Four micromolar B[a]P did not appear to induce CYP1A1 or CYP1A2 expression in DU145 or PC3 cells. The androgen dependent prostate cancer cell line, LnCap, also has constitutive expression of CYP1A1 and CYP1A2. However, both CYP1A1 and CYP1A2 are induced by treatment of LnCap cells with 4 microM B[a]P. Untreated normal prostate and primary prostate tumor cells have no detectable CYP1A1 expression. Treatment with 4 microM B[a]P induced CYP1A1 expression in both normal and primary tumor prostate cells. Constitutive CYP1A2 expression was detected in normal prostate cells with little or no induction by exposure to 4 microM B[a]P. Primary prostate tumor cells did not show constitutive expression of CYP1A2. However, CYP1A2 was induced by 4 microM B[a]P in primary prostate tumor cells. These observations indicate that hormonal and cancer specific factors affect the expression and induction of the phase I metabolic enzymes, CYP1A1 and CYP1A2 in prostate cells. These observations may be related to the potential smoking-linked higher risk of prostate cancer development and morbidity of prostate cancer patients who smoke. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14743400     DOI: 10.1002/jcb.10753

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

Review 1.  Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis.

Authors:  Benjamin A Rybicki; Nora L Nock; Adnan T Savera; Deliang Tang; Andrew Rundle
Journal:  Cancer Lett       Date:  2005-09-09       Impact factor: 8.679

2.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

3.  Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis.

Authors:  Huawen Li; Deqian Xiao; Liren Hu; Taiping He
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

4.  Racial differences in clinical and pathological associations with PhIP-DNA adducts in prostate.

Authors:  Deliang Tang; Jason J Liu; Cathryn H Bock; Christine Neslund-Dudas; Andrew Rundle; Adnan T Savera; James J Yang; Nora L Nock; Benjamin A Rybicki
Journal:  Int J Cancer       Date:  2007-09-15       Impact factor: 7.396

Review 5.  Endocrine disruptors and prostate cancer risk.

Authors:  Gail S Prins
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

6.  2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-DNA adducts in benign prostate and subsequent risk for prostate cancer.

Authors:  Deliang Tang; Oleksandr N Kryvenko; Yun Wang; Sheri Trudeau; Andrew Rundle; Satoru Takahashi; Tomoyuki Shirai; Benjamin A Rybicki
Journal:  Int J Cancer       Date:  2013-03-09       Impact factor: 7.396

7.  Polycyclic aromatic hydrocarbon--DNA adducts in prostate and biochemical recurrence after prostatectomy.

Authors:  Benjamin A Rybicki; Christine Neslund-Dudas; Cathryn H Bock; Andrew Rundle; Adnan T Savera; James J Yang; Nora L Nock; Deliang Tang
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

8.  Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.

Authors:  Nora L Nock; Deliang Tang; Andrew Rundle; Christine Neslund-Dudas; Adnan T Savera; Cathryn H Bock; Kristin G Monaghan; Allison Koprowski; Nicoleta Mitrache; James J Yang; Benjamin A Rybicki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

9.  Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate.

Authors:  Kaarthik John; Narasimhan Ragavan; M Margaret Pratt; Paras B Singh; Salah Al-Buheissi; Shyam S Matanhelia; David H Phillips; Miriam C Poirier; Francis L Martin
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

10.  CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies.

Authors:  Hongge Wang; Zhi Zhang; Sugui Han; Yujuan Lu; Fumin Feng; Juxiang Yuan
Journal:  BMC Cancer       Date:  2012-11-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.